 ADC Therapeutics SA NYSE:ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, today announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 12 clinical trial evaluating loncastuximab tesirine Lonca, formerly ADCT-402 in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL or mantle cell lymphoma MCL. 